2024 asa guidance glp-1 receptor agonists perioperative A narrative review of glucagon-like peptide-1 prior to deep sedation or general anesthesia How should we approach patients

Preclinical studies have confirmed that GIPRGLP1R coagonists improve several hallmarks of metabolic syndrome, such as obesity, hyperglycemia, and dyslipidemia

not using GLP-1 receptor agonists had significantly lower relative risks for mortality and respiratory failure, according to a presentation at the CHEST Annual Meeting.In a retrospective study, Saud Alawad, MBBS, third-year internal medicine resident at West Virginia University, and colleagues analyzed adults with a group 1 PAH

In 2024, we also saw unprecedented willingness by large numbers of patients to pay out of pocket, even in European markets, as public coverage of AOMs is still limited, at best, and more often non-existent

See how GLP-1s are reshaping diabetes & obesity care.

Discover how once-monthly maridebart cafraglutide for the treatment of obesity works, its clinical trial evidence, potential eligibility criteria, side effects, and the pathway to NHS access if approved by UK regulators.

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a well-established class of glucose-lowering drugs